SFM
LGND icon

Signet Financial Management’s Ligand Pharmaceuticals LGND Stock Holding History

Signet Financial Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-329
Closed -$32K – 833
2021
Q4 		$32K Buy
+329
New +$30.4K ﹤0.01% 674

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Signet Financial Management's LGND Position: Q1 2022 in Review

Signet Financial Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2022, closing a stake of 329 shares — an estimated $32K sold.

Signet Financial Management first reported a position in LGND in Q4 2021 and held it in 1 quarter. The position peaked at $32K in Q4 2021. 208 funds tracked by Wall St. Rank hold LGND as of Q1 2022.

  • Signet Financial Management reported no remaining Ligand Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Signet Financial Management sold 329 Ligand Pharmaceuticals shares in Q1 2022, an estimated $32K.
  • Signet Financial Management first reported a position in Ligand Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Signet Financial Management's Ligand Pharmaceuticals position peaked at $32K in Q4 2021.
  • 208 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2022.

Based on Signet Financial Management's 13F filing for Q1 2022, filed 13 May 2022.